SCHEMBL19973585

SCHEMBL19973585

CNC(=O)NC1CCCc2c(C(=O)Nc3ccc(F)c(F)c3)cccc21

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.46
TAS1R3 Q7RTX0 5/20 0.44
TAS1R1 Q7RTX1 5/20 0.44
TAS1R2 Q8TE23 4/20 0.44
NPC1 O15118 2/20 0.43
ALDH1A1 P00352 2/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TP53 P04637 1/20 0.42
MAPT P10636 2/20 0.42
MEN1 O00255 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
LMNA P02545 1/20 0.41
FPR1 P21462 1/20 0.40
FPR2 P25090 1/20 0.40
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19973584 1.00 KMT2A (0.46) KMT2ATAS1R3TAS1R1TAS1R2NPC1
SCHEMBL30450232 0.94 TP53 (0.44) KMT2ATAS1R3TAS1R1TAS1R2NPC1
SCHEMBL20509884 0.94 TP53 (0.44) KMT2ATAS1R3TAS1R1TAS1R2NPC1
SCHEMBL19973509 0.89 TP53 (0.47) KMT2ATAS1R3TAS1R1TAS1R2NPC1
SCHEMBL19973507 0.89 TP53 (0.47) KMT2ATAS1R3TAS1R1TAS1R2NPC1
SCHEMBL21189373 0.88 TAS1R3 (0.46) KMT2ATAS1R3TAS1R1TAS1R2NPC1
SCHEMBL21189386 0.85 TP53 (0.46) KMT2ATAS1R3TAS1R1TAS1R2NPC1
SCHEMBL20511808 0.82 TP53 (0.49) KMT2ATAS1R3TAS1R1TAS1R2NPC1
Hydrochloric Acid SCHEMBL26597540 0.81 TP53 (0.48) KMT2ATAS1R3TAS1R1TAS1R2NPC1
SCHEMBL19973902 0.81 TRPV1 (0.44) NPC1RAB9ASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed
WO-2018052967-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME CBX8, HAVCR2, HCCS KMT2A 155/4885TAS1R3 3760/4885TAS1R1 3802/4885
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same CBX8, HAVCR2, HCCS KMT2A 155/4885TAS1R3 3760/4885TAS1R1 3802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.